On December 9, 2025, Alpha Tau Medical Ltd. announced the successful treatment of its first patient in a U.S. trial for recurrent glioblastoma at The Ohio State University's James Cancer Hospital. This event is significant as it marks a milestone in the company's clinical efforts.